Evidence map›Paper›PMID 36765274›Full record

ArticleBMC infectious diseases2023

Disease severity in hospitalized COVID-19 patients: comparing routine surveillance with cohort data from the LEOSS study in 2020 in Germany.

Uwe Koppe, Julia Schilling, Melanie Stecher, Maria Madeleine Rüthrich, Adine Marquis, Michaela Diercke, Martina Haselberger, Carolin E M Koll, Michaela Niebank, Bettina Ruehe and 7 more

Abstract read
In one paragraph

Article in BMC infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Uwe KoppeDepartment of Infectious Disease Epidemiology, Robert Koch-Institute, Berlin, Germany. koppeu@rki.de.ORCID http://orcid.org/0000-0001-9718-5811
Julia SchillingDepartment of Infectious Disease Epidemiology, Robert Koch-Institute, Berlin, Germany.
Melanie StecherDepartment I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Maria Madeleine RüthrichCentre for Emergency Medicine, University Hospital Jena, Jena, Germany.
Adine MarquisDepartment of Infectious Disease Epidemiology, Robert Koch-Institute, Berlin, Germany.
Michaela DierckeDepartment of Infectious Disease Epidemiology, Robert Koch-Institute, Berlin, Germany.
Martina HaselbergerDepartment of Internal Medicine I, Hospital Passau, Passau, Germany.
Carolin E M KollDepartment I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Michaela NiebankCentre for Biological Threats and Special Pathogens, Robert Koch-Institute, Berlin, Germany.
Bettina RueheCentre for Biological Threats and Special Pathogens, Robert Koch-Institute, Berlin, Germany.
Stefan BorgmannDepartment of Infectious Diseases and Infection Control, Ingolstadt Hospital, Ingolstadt, Germany.
Linus GrabenhenrichDepartment for Methods Development, Research Infrastructure and Information Technology, Robert Koch Institute, Berlin, Germany.
Kerstin HellwigDepartment of Neurology, Catholic Hospital Bochum St. Josef-Hospital Bochum, Ruhr University Bochum, Bochum, Germany.
Lisa PilgramDepartment of Nephrology and Medical Intensive Care, Charité, Universitätsmedizin Berlin, Berlin, Germany.
Christoph D Spinner *Department of Internal Medicine II, School of Medicine, University Hospital Rechts Der Isar, Technical University of Munich, Munich, Germany.
Thomas Paerisch *Centre for Biological Threats and Special Pathogens, Robert Koch-Institute, Berlin, Germany.
LEOSS study group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionStudies investigating risk factors for severe COVID-19 often lack information on the representativeness of the study population. Here, we investigate factors associated with severe COVID-19 and compare the representativeness of the dataset to the general population.

methodsWe used data from the Lean European Open Survey on SARS-CoV-2 infected patients (LEOSS) of hospitalized COVID-19 patients diagnosed in 2020 in Germany to identify associated factors for severe COVID-19, defined as progressing to a critical disease stage or death. To assess the representativeness, we compared the LEOSS cohort to cases of hospitalized patients in the German statutory notification data of the same time period. Descriptive methods and Poisson regression models were used.

resultsOverall, 6672 hospitalized patients from LEOSS and 132,943 hospitalized cases from the German statutory notification data were included. In LEOSS, patients above 76 years were less likely represented (34.3% vs. 44.1%). Moreover, mortality was lower (14.3% vs. 21.5%) especially among age groups above 66 years. Factors associated with a severe COVID-19 disease course in LEOSS included increasing age, male sex (adjusted risk ratio (aRR) 1.69, 95% confidence interval (CI) 1.53-1.86), prior stem cell transplantation (aRR 2.27, 95% CI 1.53-3.38), and an elevated C-reactive protein at day of diagnosis (aRR 2.30, 95% CI 2.03-2.62).

conclusionWe identified a broad range of factors associated with severe COVID-19 progression. However, the results may be less applicable for persons above 66 years since they experienced lower mortality in the LEOSS dataset compared to the statutory notification data.

Indexed as

COVID-19Hematopoietic Stem Cell TransplantationAgedGermanyHospitalizationHumansMalePatient AcuitySARS-CoV-2COVID-19LEOSSSARS-CoV-2Severe COVIDStatutory notification

Identifiers

PMID36765274
PMCPMC9912207

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.